GlassScriptPhysician profile
Colleen Vargovich
NPI 1326716267
$792.22
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.84 · 2022: $693.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $160.99 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $70.85 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $64.92 | 2022 | |
| Sunovion Pharmaceuticals INC. | $59.33 | 2022 | |
| Nestle Healthcare Nutrition INC. | $56.58 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $55.28 | 2022 | |
| Global Blood Therapeutics, INC. | $54.33 | 2022 | |
| Urovant Sciences INC | $48.42 | 2022 | |
| Janssen Pharmaceuticals, INC | $44.01 | 2022 | |
| Abbvie INC. | $38.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $35.15 | 2021 | |
| Acadia Pharmaceuticals INC | $34.61 | 2022 | |
| Daiichi Sankyo INC. | $26.84 | 2022 | |
| Evoke Pharma, INC. | $24.98 | 2022 | |
| Dexcom, INC. | $17.83 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Vargovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.